Literature DB >> 23265881

Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.

Agustin Casimiro-Garcia1, Ronald J Heemstra, Christopher F Bigge, Jing Chen, Fred A Ciske, Jo Ann Davis, Teresa Ellis, Nadia Esmaeil, Declan Flynn, Seungil Han, Mehran Jalaie, Jeffrey F Ohren, Noel A Powell.   

Abstract

Identification of a series of imidazo[4,5-c]pyridin-4-one derivatives that act as dual angiotensin II type 1 (AT1) receptor antagonists and peroxisome proliferator-activated receptor-γ (PPARγ) partial agonists is described. Starting from a known AT1 antagonist template, conformational restriction was introduced by incorporation of an indane ring that when combined with appropriate substitution at the imidazo[4,5-c]pyridin-4-one provided novel series 5 possessing the desired dual activity. The mode of interaction of this series with PPARγ was corroborated through the X-ray crystal structure of 12b bound to the human PPARγ ligand binding domain. Modulation of activity at both receptors through substitution at the pyridone nitrogen led to the identification of potent dual AT1 antagonists/PPARγ partial agonists. Among them, 21b was identified possessing potent dual pharmacology (AT1 IC(50) = 7 nM; PPARγ EC(50) = 295 nM, 27% max) and good ADME properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265881     DOI: 10.1016/j.bmcl.2012.11.088

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.

Authors:  Jun Zhang; Qing-Qing Hao; Xin Liu; Zhi Jing; Wen-Qing Jia; Shu-Qing Wang; Wei-Ren Xu; Xian-Chao Cheng; Run-Ling Wang
Journal:  Oncotarget       Date:  2017-04-11

2.  Rational design of stapled helical peptides as antidiabetic PPARγ antagonists to target coactivator site by decreasing unfavorable entropy penalty instead of increasing favorable enthalpy contribution.

Authors:  Yang Zhang; Jie Wang; Wenchao Li; Ying Guo
Journal:  Eur Biophys J       Date:  2022-09-04       Impact factor: 2.095

Review 3.  Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism.

Authors:  Alice J Kroker; John B Bruning
Journal:  PPAR Res       Date:  2015-09-08       Impact factor: 4.964

Review 4.  Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.

Authors:  Malwina Krause; Henryk Foks; Katarzyna Gobis
Journal:  Molecules       Date:  2017-03-04       Impact factor: 4.411

5.  Tuning Cross-Coupling Approaches to C3 Modification of 3-Deazapurines.

Authors:  Łukasz J Weseliński; Vagarshak Begoyan; Alexis Ferrier; Marina Tanasova
Journal:  ACS Omega       Date:  2017-10-20

Review 6.  Multi-Target Approaches in Metabolic Syndrome.

Authors:  Felix F Lillich; John D Imig; Ewgenij Proschak
Journal:  Front Pharmacol       Date:  2021-03-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.